Conference Call Schedules, Clinical Trial Studies, Awards and Accolades, Appointments, and Welfare Initiatives - Analyst Notes on Celgene, Johnson & Johnson, Merck, Sanofi, and UnitedHealth

NEW YORK, April 8, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Sanofi (NYSE: SNY), and UnitedHealth Group, Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Celgene Corporation Analyst Notes 

On April 1, 2014, Celgene Corporation (Celgene) announced that it will host a conference call and live audio webcast on Thursday, April 24, 2014 at 9:00 a.m. ET, to discuss its Q1 2014 financial and operational results. The Company informed that the webcast can be accessed on Celgene's website. According to Zacks Investment Research data, the consensus EPS estimate for Q1 2014 is $1.43. The full analyst notes on Celgene Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04082014/CELG/report.pdf

Johnson & Johnson Analyst Notes 

On April 2, 2014, Janssen R&D Ireland, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that two Phase 3 trials are recruiting patients to evaluate the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naïve and treatment-experienced patients with and without cirrhosis. The first trial, known as OPTIMIST-1 (Optimal Treatment with a simeprevir and sofosbuvir Therapy) or TMC435HPC3017, is a Phase 3, multicenter, open-label, randomized study investigating the efficacy and safety of simeprevir 150 mg in combination with sofosbuvir 400 mg. And the second trial, known as OPTIMIST-2 or TMC435HPC3018, is a Phase 3, multicenter, open-label, single-arm study investigating the efficacy and safety of simeprevir 150 mg in combination with sofosbuvir 400 mg. According to the Company, the combination will be run once daily for 12 weeks in HCV genotype 1 infected patients with cirrhosis who are HCV treatment naïve or treatment experienced. The full analyst notes on Johnson & Johnson are available to download free of charge at:

http://www.AnalystsReview.com/04082014/JNJ/report.pdf

Merck & Co. Inc. Analyst Notes 

On April 3, 2014, Merck & Co. Inc. (Merck) announced that it has been awarded with the ENERGY STAR 2014 Partner of the Year - Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors. Merck informed that it has been an ENERGY STAR partner since 1995 and recognized by the EPA for nine consecutive years, twice as Partner of the Year and now a seventh time for Sustained Excellence. The Company stated that the award recognizes four Merck manufacturing sites that have achieved ENERGY STAR rankings in the top 25% of pharmaceutical plant energy performance nationwide: Arecibo, Puerto Rico, Cleveland, Tenn., Las Piedras, Puerto Rico; and Elkhorn, Neb. The full analyst notes on Merck & Co. Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04082014/MRK/report.pdf

Sanofi Analyst Notes 

On March 31, 2014, Sanofi announced the appointment of Anne C. Beal, M.D., MPH, to the newly created position of Chief Patient Officer. In his new role, Dr. Beal will be responsible to further elevate the perspective of the patient within Sanofi so the company's future healthcare offerings can better incorporate the unique priorities and needs of patients and caregivers in a variety of Sanofi activities, ranging from early stage R&D through to on-market availability of novel healthcare solutions. Commenting on the appointment, Pascale Witz, Executive Vice President, Global Divisions and Strategic Development at Sanofi, said, "Interactions with patients are a source of strength for the company and Dr. Beal's appointment will help ensure the patient perspective advances our approach to meeting the unmet needs of patients." The full analyst notes on Sanofi are available to download free of charge at:

http://www.AnalystsReview.com/04082014/SNY/report.pdf

UnitedHealth Group, Inc. Analyst Notes 

On April 1, 2014, UnitedHealth Children's Foundation (UHCCF) launched its new "Little Book - Big Laughs Joke Book" to deliver smiles to children young and old and raise funds for children with health needs. The Company informed that the book features more than 600 jokes submitted by kids, for kids. Jokes include popular and original jokes, funny one-liners, knock-knock jokes and silly tongue-twisters. The proceeds from the book will be used to fund future UHCCF grants that help families pay for children's medical expenses not covered, or not fully covered, by a commercial health insurance plan. Commenting on the initiative, UHCCF President Matt Peterson, said, "At the heart of the book is our desire to create an uplifting, boredom-busting read to inspire any reader, whether in a hospital or waiting room, or on a long car ride. The book's proceeds will help provide child medical grants to families in need." The full analyst notes on UnitedHealth Group, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04082014/UNH/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review